Skip to main content

Table 2 Organ transplant recipients: immunosuppressive therapy

From: Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

Patient ID (age)

Organs transplanted

Immunosuppressive regimen

Year initiated

203 (65 y)

kidney

Mycophenolate mofetil 500 mg QD

1995

207 (45 y)

kidney

Cyclosporine 175 mg BID; Azathioprine 100 mg QD

1994

208 (32 y)

kidney + pancreas

Mycophenolate mofetil 500 mg BID; Tacrolimus 2 mg BID

2000

211 (47 y)

kidney + pancreas

Cyclosporine 150 mg BID; Azathioprine 50 mg QD

1991

214 (55 y)

kidney

Cyclosporine 125 mg TID

1991

233 (41 y)

kidney x 2

Cyclosporine 75 mg BID; Azathioprine 50 mg QD

1993*

238 (51 y)

kidney

Cyclosporine 50 mg BID; Mycophenolate mofetil 1000 mg BID

1999

  1. *Year of second kidney transplant. The regimen taken between 1988 (year of first kidney transplant) and 1993 was not recorded.